- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.03. | Sera Prognostics outlines plan to expand partner programs to 15-17 states by year-end 2026 while maintaining cash runway through 2028 | 1 | Seeking Alpha | ||
| 18.03. | Sera Prognostics: Aktie fällt trotz Gewinnüberraschung nach schwachen Umsatzzahlen | 2 | Investing.com Deutsch | ||
| 18.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter And Full Year 2025 Financial Results | 265 | PR Newswire | SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 18.03. | Sera Prognostics: EPS übertrifft Schätzungen um 0,03 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 18.03. | SERA PROGNOSTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 18.03. | SERA PROGNOSTICS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 18.03. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | Sera Prognostics: Positive Studiendaten zu Frühgeburtentest beflügeln Aktie | 1 | Investing.com Deutsch | ||
| 07.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 15.12.25 | Jefferies initiates Sera Prognostics stock with Buy rating on preterm birth test | 1 | Investing.com | ||
| 15.12.25 | Jefferies stuft Sera Prognostics mit "Buy" ein - Frühgeburtentest als Kurstreiber | 3 | Investing.com Deutsch | ||
| 14.11.25 | Sera Prognostics outlines accelerated Medicaid pilot expansion to 13 states as commercialization momentum builds | 1 | Seeking Alpha | ||
| 13.11.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2025 Financial Results | 825 | PR Newswire | SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 13.11.25 | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.10.25 | Sera Prognostics, Inc.: Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer | 204 | PR Newswire | SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen | |
| 06.08.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2025 Financial Results | 157 | PR Newswire | SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 08.05.25 | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 340 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
| 07.05.25 | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 409 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,485 | -3,26 % | NanoRepro im Umbau: Beteiligungen liefern Wachstum - wird daraus die nächste Consumer-Health-Story? | NanoRepro AG steckt mitten in der Transformation - weg vom klassischen Schnelltestanbieter hin zu einer integrierten Consumer-Health-Plattform. Die Zahlen für 2025 zeigen: Operativ wird bewusst gebremst... ► Artikel lesen | |
| OCUGEN | 1,414 | -0,56 % | Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk | ||
| VIKING THERAPEUTICS | 28,050 | +0,18 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,480 | -0,67 % | Cosciens Biopharma Inc: Cosciens Biopharma to exit U.S. reporting | ||
| SCORPIUS | - | - | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 7,620 | -0,18 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart adds James Breitmeyer to board of directors | ||
| IBIO | 1,439 | +0,07 % | iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 | ||
| REDHILL BIOPHARMA | 1,025 | +1,49 % | RedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,570 | -0,28 % | Arbutus Biopharma Corporation: Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B | Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,442 | -1,50 % | Cardiff Oncology präsentiert auf ASCO-Jahrestagung Daten zu Darmkrebsstudie | ||
| MANNKIND | 2,415 | +4,59 % | MannKind Announces Settlement of Convertible Senior Notes | DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal... ► Artikel lesen | |
| ALDEYRA | 1,360 | +2,26 % | Aldeyra Therapeutics: Aufsichtsratsmitglied Martin J. Joyce tritt nicht zur Wiederwahl an | ||
| TRAWS PHARMA | 1,160 | -4,13 % | Traws Pharma, Inc.: Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal ... | Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID- with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,450 | -2,68 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen |
SERA PROGNOSTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,080 (-3,83 %) liegt der Kurs bei 2,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.